Lundbeck enters licensing agreement for antidepressant in India

Danish pharmaceutical firm Lundbeck has partnered up with Sun Pharmaceutical Industries in India.

Photo: Jens Dresling

Lundbeck has entered into a licensing agreement with Sun Pharmaceutical Industries, giving the latter exclusive rights to sell antidepressant drug vortioxentine in India.

Sun Pharmaceutical Industries plans to market the treatment under the name Vortidif, while Lundbeck itself markets the drug under the names of Brintellix and Trintellix.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs